Welcome to the Department of Radiation Oncology
Message from James M. Metz, MD — Chairman
Penn Radiation Oncology is dedicated to a three-part mission of excellence in patient care, basic and translational research, and the education of residents and students. We are committed to delivering excellence in every area and as such we steadfastly believe that “Excellence is Standard.”
Penn Radiation Oncology is one of the most comprehensive radiation oncology programs in the world. The outstanding faculty and staff, combined with Penn’s extensive collection of advanced technology, gives patients access to nearly every treatment option available for their cancer. The broad range of radiation treatments available include proton therapy, intensity-modulated radiation therapy (IMRT), high-dose rate (HDR) and low-dose rate brachytherapy, partial breast irradiation, stereotactic radiosurgery (SRS), and Gamma Knife radiation. With the Abramson Cancer Center of the University of Pennsylvania, Penn Radiation Oncology provides patient care at the Ruth and Raymond Perelman Center for Advanced Medicine and seven community-based sites.
Read more of the Message from the Chair »
- Penn Receives $12 Million Grant to Study Connection Between Radiation and Immunotherapies
June 3, 2019
The Mark Foundation for Cancer Research’s award establishes new center within the Abramson Cancer Center
- One Simple Change Cut Unnecessary Imaging for Cancer Patients in Half
June 27, 2019
A “nudge” is helping shorten treatment time for patients with advanced cancer. Simply introducing a default physician order — a “nudge” — into electronic health records (EHRs) cut the use of unnecessary daily imaging in half during palliative radiation therapy sessions for patients with advanced cancer, according to a Penn Medicine study published in JAMA Oncology
Penn Medicine News Update:
Researchers Identify in Mouse Models a New Way to Make Cancer Self Destruct
A research team in the Perelman School of Medicine of the University of Pennsylvania, led by, Constantinos Koumenis, PhD, have identified a new pathway that works as a partner to MYC and may be its Achilles’ Heel. The pathway involves a protein called ATF4, and when it’s blocked, it can cause cancer cells to produce too much protein and die. These findings in cell lines and mouse models could point the way toward a new therapeutic approach as inhibitors that can block synthesis of ATF4 already exist. Published in Nature Cell Biology.
Medical Physics Graduate Programs Relaunched
The Master of Medical Physics and Certificate in Medical Physics programs are excited to welcome our first class to our new home in the Perelman School of Medicine for Fall semester 2019.
Please see our new Medical Residency Brochure
Department of Radiation Oncology Newsletters
© The Trustees of the University of Pennsylvania | Site best viewed in a supported browser. | Report Accessibility Issues and Get Help | Site Design: PMACS Web Team.